Original Article
Coronary Intervention for Persistent Occlusion after Myocardial Infarction
N Engl J Med 2006; 355:2395-2407December 7, 2006
- Abstract
Background
It is unclear whether stable, high-risk patients with persistent total occlusion of the infarct-related coronary artery identified after the currently accepted period for myocardial salvage has passed should undergo percutaneous coronary intervention (PCI) in addition to receiving optimal medical therapy to reduce the risk of subsequent events.
Methods
We conducted a randomized study involving 2166 stable patients who had total occlusion of the infarct-related artery 3 to 28 days after myocardial infarction and who met a high-risk criterion (an ejection fraction of <50% or proximal occlusion). Of these patients, 1082 were assigned to routine PCI and stenting with optimal medical therapy, and 1084 were assigned to optimal medical therapy alone. The primary end point was a composite of death, myocardial reinfarction, or New York Heart Association (NYHA) class IV heart failure.
Results
The 4-year cumulative primary event rate was 17.2% in the PCI group and 15.6% in the medical therapy group (hazard ratio for death, reinfarction, or heart failure in the PCI group as compared with the medical therapy group, 1.16; 95% confidence interval [CI], 0.92 to 1.45; P=0.20). Rates of myocardial reinfarction (fatal and nonfatal) were 7.0% and 5.3% in the two groups, respectively (hazard ratio, 1.36; 95% CI, 0.92 to 2.00; P=0.13). Rates of nonfatal reinfarction were 6.9% and 5.0%, respectively (hazard ratio, 1.44; 95% CI, 0.96 to 2.16; P=0.08); only six reinfarctions (0.6%) were related to assigned PCI procedures. Rates of NYHA class IV heart failure (4.4% vs. 4.5%) and death (9.1% vs. 9.4%) were similar. There was no interaction between treatment effect and any subgroup variable (age, sex, race or ethnic group, infarct-related artery, ejection fraction, diabetes, Killip class, and the time from myocardial infarction to randomization).
Conclusions
PCI did not reduce the occurrence of death, reinfarction, or heart failure, and there was a trend toward excess reinfarction during 4 years of follow-up in stable patients with occlusion of the infarct-related artery 3 to 28 days after myocardial infarction. (ClinicalTrials.gov number, NCT00004562.)
Media in This Article
Figure 1
Kaplan–Meier Curves for the Primary End Point, According to the Intention-to-Treat Analysis.Figure 2
Kaplan–Meier Curves for the Secondary End Points, According to the Intention-to-Treat Analysis.Article Activity
- Article
Optimal treatment for patients who have acute myocardial infarction with ST-segment elevation includes early reperfusion with primary percutaneous coronary intervention (PCI) or thrombolytic therapy. However, approximately one third of eligible patients do not receive early reperfusion therapy, in many cases because of late presentation.1,2
The best strategy for the care of patients with persistent total occlusion of the infarct-related artery who are identified after the currently accepted period during which reperfusion is administered for myocardial infarction is unclear. Most observational studies have reported that lower event rates are associated with patency of the infarct-related artery late after myocardial infarction, as compared with persistent occlusion, but the results of a large database study and small clinical trials of routine PCI have been inconclusive.3-11
The clinical approach to the occluded infarct-related artery late after myocardial infarction remains variable and controversial, but there is strong bias in favor of PCI, particularly in the United States.12-15 Mechanisms by which late PCI of an occluded infarct-related artery might improve outcomes include reduction in adverse left ventricular remodeling with preservation of left ventricular function,5,7,16 increased electrical stability, and the provision of collateral vessels to other coronary beds for protection against future events.17,18 Late PCI also has the potential for harm from procedure-related complications, distal embolization of atherothrombotic debris resulting in myocardial injury, and loss of recruitable collateral flow to other coronary territories.19,20
We report the results of the Occluded Artery Trial (OAT), which tested the hypothesis that a strategy of routine PCI for total occlusion of the infarct-related artery 3 to 28 days after acute myocardial infarction would reduce the occurrence of a composite end point of death, reinfarction, or New York Heart Association (NYHA) class IV heart failure.
Methods
The methods used in the trial have been described previously.21 Sponsorship and oversight of the trial were provided by the National Heart, Lung, and Blood Institute (NHLBI). Corporate support from several sources accounted for 6% of the total funding and in-kind support for the trial, as described in the support statement. A data and safety monitoring board appointed by the NHLBI oversaw the conduct of the trial and monitored treatment effects. Institutional review boards at the participating centers approved the study protocol, and all patients provided written informed consent. In the preparation of this report, data management and the statistical analysis were performed by the data coordinating center with oversight by the academic authors, who had full access to the data and vouch for the accuracy and completeness of the data and the analysis. The companies that provided financial support, products, or both had no role in the study design, analysis, or interpretation of the results or in the decision to submit the manuscript for publication.
Study Population
Patients were eligible for enrollment if coronary angiography, performed 3 to 28 days after myocardial infarction, showed total occlusion of the infarct-related artery with poor or absent antegrade flow, defined as a Thrombolysis in Myocardial Infarction (TIMI) flow grade of 0 or 1, and if they met a criterion for increased risk, defined as an ejection fraction of less than 50% (assessed by echocardiography, radionuclide ventriculography, or contrast ventriculography), proximal occlusion of a major epicardial vessel with a large risk region, or both.21 Qualifying angiograms were reviewed at a core angiography laboratory. The qualifying period of 3 to 28 days was based on calendar days; day 1 was the day of the onset of symptoms. Thus, the minimal time from the myocardial infarction to angiography was just over 24 hours. Exclusion criteria were NYHA class III or IV heart failure, shock, a serum creatinine concentration higher than 2.5 mg per deciliter (221 μmol per liter), angiographically significant left main or three-vessel coronary artery disease, angina at rest, and severe ischemia on stress testing (which was required if the infarct zone was not akinetic or dyskinetic).21
Treatment
Patients were randomly assigned to PCI with stent placement and optimal medical therapy or optimal medical therapy alone. Randomization was performed with the use of an interactive automated telephone-response system; a permuted-block design was used to generate random allocations within each study site.
All patients received optimal medical therapy, including aspirin, anticoagulation if indicated, angiotensin-converting–enzyme inhibition, beta-blockade, and lipid-lowering therapy, unless contraindicated. Thienopyridine therapy was initiated before PCI and continued for 2 to 4 weeks in patients who underwent stenting. After reports of the efficacy of prolonged treatment with a thienopyridine,22,23 a thienopyridine was recommended in the two study groups for 1 year after myocardial infarction.
Patients assigned to PCI were to undergo the procedure within 24 hours after randomization. Use of glycoprotein IIb/IIIa inhibitors was strongly recommended. Stenting was recommended for the occluded segment as well as for high-grade stenoses in major proximal or distal segments, whenever technically feasible in the PCI group. PCI for stenoses in non–infarct-related arteries was permitted in the two groups.
Images from the PCI were reviewed at the angiography core laboratory.21 Successful PCI was defined as an open artery with residual stenosis of less than 50% and a TIMI flow grade of 2 or 3. PCI was also considered to be successful if there was an optimal epicardial result, accompanied by a TIMI antegrade flow grade of 1 presumed to be due exclusively to microvascular obstruction. Cardiac markers (preferably creatine kinase MB [CK-MB] or, if not available, troponin I or T or creatine kinase) were to be measured routinely in both groups three times during the first 48 hours after randomization and within 24 hours after PCI in patients assigned to PCI.
Ancillary Studies
A subgroup of 124 patients underwent baseline viability scanning with the use of single-photon-emission computed tomography (SPECT) and technetium-99m–labeled sestamibi (after the administration of nitroglycerin and while the patient was at rest) to assess myocardial viability before the patient received the assigned treatment.21 In a subgroup of 381 patients, cardiac catheterization was repeated at 1 year.
End Points
The study end-point events were adjudicated by an independent mortality and morbidity classification committee, which was unaware of the treatment assignments. The primary end point was a composite of death from any cause, reinfarction, or NYHA class IV heart failure with hospitalization or admission for a stay in a short-stay unit. Secondary end points included the separate components of the primary end point as well as symptoms and other clinical events.
The prespecified definition of reinfarction required two of the following three criteria: the persistence of symptoms for 30 or more minutes, electrocardiographic changes, and elevated cardiac markers. Elevations were defined as follows: a creatine kinase concentration that was two or more times the upper limit of the normal range used by the local laboratory, a CK-MB fraction that was greater than the upper limit of the normal range, and a troponin I or T level that was two or more times the upper limit of the normal range.
A diagnosis of reinfarction after revascularization also required two of three criteria; elevation of a cardiac marker was defined as more than three times the upper limit of the normal range in patients who had undergone PCI and more than five times the upper limit of the normal range in those who had undergone coronary-artery bypass grafting (CABG). Troponin levels were not used to diagnose reinfarction within 10 days after the index myocardial infarction.
Reinfarction was centrally adjudicated. Site-determined reinfarctions included those locally diagnosed or suspected and those reported in association with hospitalization for other events after central review suggested that reinfarction had occurred (e.g., on the basis of cardiac marker elevations). An additional prespecified end point was recurrent elevation of a cardiac marker within 48 hours after randomization, as reported by the sites.
Statistical Analysis
It was initially estimated that 3200 patients would be required for the study to have 90% power to detect a 25% reduction in the rate of the primary end-point event in patients undergoing PCI, assuming a 3-year event rate of 25% with medical therapy, a 25% crossover rate (including patients who crossed over from medical therapy alone to PCI and those in whom PCI was not attempted or failed), and a 5% loss to follow-up. Subsequently, the study leadership, with the approval of the data and safety monitoring board, reduced the recruitment goal to 2400 patients because of recruitment challenges and a crossover rate that was less than expected. The final enrollment of 2166 patients (90% of the target population) afforded 94% power to detect the anticipated difference in the primary end point. To adjust for interim testing, a two-sided significance level of 0.0456 was specified for the comparison of the primary end point between the two groups and a significance level of 0.01 for the secondary end points.21
Estimates of the cumulative event rate were calculated by the Kaplan–Meier product-limit method,24 and treatments were compared with the use of log-rank tests of the 5-year curves.25 The 4-year event rates are presented because the number of patients followed for 5 years was small. Data for patients lost to follow-up were censored as of the time of the last contact. Analyses were performed according to the intention-to-treat principle, except in the as-treated analysis. Categorical variables were compared with the use of the chi-square test, and continuous variables were compared with the use of Student's t-test.
Prespecified subgroup analyses of the primary outcome were performed by Cox proportional-hazards regression,26 with each test (regression coefficient) performed at an alpha level of 0.01, with tests for interaction. Other, a posteriori subgroup analyses were also performed. To generate the covariate-adjusted hazard ratio, we used a Cox proportional-hazards regression model with eight covariates of interest (six that were preidentified plus the presence or absence of diabetes and the Killip class), with interactions of these covariates with treatment included in the model. The final model included the treatment group, regardless of its significance, and covariates and interactions with a significance level of 0.01 or less were retained. The exponentiation of the coefficient for the treatment group in this model, adjusted for the other terms in the model, yielded the hazard ratio and, combined with the standard error of the coefficient, the confidence interval (CI).
The protocol specified a significance level of 0.01 or less for secondary end points, including subgroup tests of interactions. At the request of the Journal editors, we present 95% CIs, instead of 99% CIs.
Results
Baseline Characteristics
Between February 2000 and December 2005, 2166 patients were enrolled in the trial (as described in detail in the Supplementary Appendix, available with the full text of this article at www.nejm.org). Of these, 1082 were randomly assigned to routine PCI plus optimal medical therapy, and 1084 to optimal medical therapy alone. The baseline characteristics of the patients in the two groups were similar except for a higher prevalence of diabetes in the group assigned to medical therapy (Table 1Table 1
Baseline Clinical and Angiographic Core Laboratory Characteristics.).The angiographic core laboratory confirmed the angiographic eligibility of 99% of patients who underwent randomization. Baseline SPECT data from the ancillary study to assess myocardial viability showed at least moderately preserved viability of the infarct zone (>40% of peak tracer uptake) in 69% of the 124 patients.
PCI Procedural Data
PCI of the qualifying occlusion was attempted in 1071 of the 1082 patients in the PCI group (99%) and was successful in 937 (87%); 869 of 1056 patients in the PCI group (82%) for whom the TIMI flow was reported after the procedure had a TIMI flow grade of 3. At least one stent was placed in 945 of 1082 patients (87%) in the PCI group, of whom 77 (8%) received drug-eluting stents. Glycoprotein IIb/IIIa antagonists were administered to 72% of the patients in whom PCI was successful. PCI of an artery other than the infarct-related artery was performed in 7% of the patients in this group and in 6% of those in the medical therapy group. Major PCI-related complications were rare (death, 0.2% of patients in the PCI group; centrally adjudicated myocardial reinfarction, 0.6%; NYHA class IV heart failure, 0.2%; cardiac tamponade, 0.2%; and stroke, 0.1%).
Among the 1084 patients in the medical therapy group, 27 (3%) crossed over to PCI within 30 days after randomization, and an additional 63 (6%) crossed over after 30 days. Four patients (0.4%) in each of the two groups underwent CABG within 30 days after randomization.
Concomitant Medical Therapy
At discharge, the rates of use of medication, as recommended in the guidelines of the American College of Cardiology and the American Heart Association,27 were high (Table 2Table 2
Medication Use on Discharge.). A thienopyridine was administered to more than 99% of patients in the PCI group in whom PCI with stenting was successful. Medication use was similar in the two groups, except for higher rates of use of anticoagulant agents, nitrates, and hypoglycemic agents in the medical therapy group (Table 2). Overall, thienopyridines were used more frequently in the PCI group at both 4 months and 1 year than in the medical therapy group.Follow-up
In the subgroup of patients who underwent repeated angiography, the infarct-related artery was patent at 1 year in 83% of 173 patients in the PCI group (89% of those in whom PCI was initially successful) and in 25% of 159 patients in the medical therapy group (P<0.001). Details of this angiographic substudy are reported elsewhere.28
The mean (±SE) follow-up was 1059±11 days, and it was similar in the two groups. Only 1% of patients (15 patients in each of the two groups) were lost to follow-up before the occurrence of a primary end-point event or 12 months of follow-up (see the Supplementary Appendix). Vital status was not ascertained for 20 of these patients (8 in the PCI group and 12 in the medical therapy group).
Primary Outcome
The centrally adjudicated primary outcome (death from any cause, nonfatal reinfarction, or NYHA class IV heart failure) occurred in 161 patients in the PCI group as compared with 140 in the medical therapy group (Table 3Table 3
Primary and Secondary Outcomes.). The estimated 4-year cumulative primary event rate was 17.2% in the PCI group and 15.6% in the medical therapy group (unadjusted hazard ratio for the PCI group as compared with the medical therapy group, 1.16; 95% CI, 0.92 to 1.45; P=0.20; covariate-adjusted hazard ratio, 1.17; 95% CI, 0.93 to 1.47; P=0.18) (Figure 1Figure 1Kaplan–Meier Curves for the Primary End Point, According to the Intention-to-Treat Analysis.). In an as-treated analysis comparing 937 patients in the PCI group in whom PCI was successful on angiographic examination with 1057 patients in the medical therapy group who did not cross over to PCI within 30 days after randomization, the hazard ratio for the primary outcome was 1.15 for PCI as compared with medical therapy (95% CI, 0.91 to 1.46; P=0.26).Primary end-point events as determined at the study sites occurred in 170 patients in the PCI group and 142 patients in the medical therapy group (hazard ratio, 1.22; 95% CI, 0.97 to 1.52; P=0.09). The lower rates of adjudicated primary end-point events as compared with site-determined events largely reflect lower rates of reinfarction that met the more stringent adjudicated study definition of events.
Secondary Outcomes
On the basis of the study definition of reinfarction, there was no significant difference in the number of confirmed reinfarctions between the PCI group and the medical therapy group (Table 3 and Figure 2Figure 2
Kaplan–Meier Curves for the Secondary End Points, According to the Intention-to-Treat Analysis.). The rate of site-determined reinfarction tended to be higher in the PCI group (hazard ratio, 1.37; 95% CI, 1.00 to 1.89; P=0.05). There were no significant differences between the groups for the other components of the primary end point or other secondary end points. There was a trend toward more frequent coronary revascularization in the medical therapy group than in the PCI group.There were significantly fewer patients with angina in the PCI group at 4 months and at 1 year (see the Supplementary Appendix). Over time, the occurrence of angina declined in both study groups, as did the difference between the two groups, and by 3 years there was no significant difference between the groups.
Subgroup Analysis
There was no significant interaction (P<0.01) between treatment effect and any subgroup variable (Figure 3Figure 3
Subgroup Analysis.). There were also no significant differences for the primary end point according to the country where patients were enrolled (United States or other countries) or according to the enrollment period (before 2002, 2002 to June 2003, or July 2003 to December 2005).Discussion
The late open-artery hypothesis asserts that the mechanical opening of a persistently occluded infarct-related artery at a time too late for myocardial salvage should improve the long-term outcome. Our study showed high rates of procedural success with PCI and sustained patency but no clinical benefit during an average 3-year follow-up with respect to death, reinfarction, or heart failure, contrary to the hypothesis. Moreover, a trend toward an excess risk of reinfarction in the PCI group aroused concern.
These unexpected results were remarkably consistent among all subgroups, including patients at highest risk for adverse left ventricular remodeling (patients with a low ejection fraction or an anterior myocardial infarction). The trend (P=0.05) toward an interaction based on age may be a chance finding. An as-treated analysis that excluded patients in whom PCI failed and patients who crossed over from medical therapy to PCI within 30 days showed no trend toward a benefit from PCI.
There was no statistically significant between-group difference in the rate of reinfarction according to the adjudicated, conservative definition of myocardial infarction. However, the event curves showed a trend that aroused concern. Site-determined reinfarctions better reflect the international consensus document that redefined myocardial infarction, published after the inception of our trial, which relies primarily on cardiac markers.29 Our analysis showed that patients in the PCI group tended to have excess reinfarctions, which were mostly due to events not temporally related to the procedure. There was also a higher rate of release of cardiac markers early after randomization in the PCI group that did not meet the trial criteria for myocardial infarction. The clinical consequences of reinfarction in this circumstance remain to be investigated.
The mechanisms of early and late myocardial damage in this trial may be different. The excess early release of a cardiac marker may be a consequence of distal atherothrombotic embolization and microvascular plugging related to PCI. Although the risk of reinfarction appeared to be greatest during the first 30 days after PCI, a trend toward an increased risk persisted throughout the 5-year follow-up. These reinfarctions occurred despite thienopyridine use at discharge in more than 99% of patients in whom PCI had been successful. However, information on whether events occurred while these agents were being taken is not available. We speculate that the loss of rapidly recruitable collateral flow after PCI of the total occlusion30 could have predisposed patients in the PCI group to reinfarction in the event of spontaneous reocclusion. Indeed, patients in the nuclear imaging ancillary study had, on average, sufficient viability (69% with moderate retained viability in the infarct zone) to explain reinfarction within the same region.
Experimental studies, with support from observational studies, have shown that late reperfusion reduces infarct expansion and adverse left ventricular remodeling.5,16,31-33 A strong association between a patent infarct-related artery at hospital discharge and improved clinical outcomes after myocardial infarction has been reported in post hoc analyses, but in the largest database analysis, this association was not independent at 1 year.8-11 Small randomized trials of PCI versus medical therapy for total occlusion in the subacute phase of myocardial infarction have had conflicting results regarding left ventricular function and size and clinical events, ranging from benefit to harm for each end point. Data from three of four studies show a range of reinfarction rates that are 1.5 to 3.5 times higher in the PCI group than in the medical therapy group (Zagler A: personal communication).3,6,7 The angiographic ancillary substudy showed a similar ejection fraction in the two groups at 1 year. The assignment to PCI appeared to be predictive of a somewhat smaller increase in the left ventricular volume in a subgroup of patients for whom volume measurements were available.28 A potential benefit of attenuation of left ventricular remodeling may be countered by excess nonfatal reinfarctions.
The results of our study should be considered in the context of the available medical and interventional therapeutics. In contrast to previous studies examining the late open-artery hypothesis, our study used high rates of glycoprotein IIb/IIIa antagonists and stents, reflecting best practices for the period of enrollment34; patency rates at 1 year were high. Drug-eluting stents were approved during the later years of recruitment. Randomized trials comparing drug-eluting stents and bare-metal stents have shown no reduction in the components of our primary end point with the use of drug-eluting stents. On the contrary, there is growing concern regarding the increased risk of late thrombosis with the use of drug-eluting stents, as compared with bare-metal stents.35,36 Moreover, trials of thrombectomy and distal-protection devices to prevent downstream embolization during PCI for myocardial infarction with ST-segment elevation have yielded disappointing results.37,38
In summary, our study involving 2166 patients showed no reduction in major cardiovascular events during a mean follow-up of 3 years. There was a trend toward excess nonfatal reinfarction when routine PCI was performed in stable patients who were found to have occlusion of the infarct-related artery 3 to 28 days after myocardial infarction.
Supported by grants from the NHLBI (U01 HL062509 to Dr. Hochman, R01 HL67683 to Dr. Dzavik, U01 HL062257 to Dr. Mark, and U01 HL062511 to Dr. Knatterud). Boston Scientific (Argentina) and Cordis, a Johnson & Johnson company, donated stents for the Argentine study sites (in-kind support equivalent to 0.003% of the total funding) and OAT study sites (in-kind support equivalent to 0.61% of the total funding); Eli Lilly donated replacement doses of abciximab (ReoPro) and funding for meetings (in 2001, 2002, and 2006) (in-kind and monetary support equivalent to 2.69% of the total funding); Guidant donated funds for the pilot phase and stent reimbursement for one site and stents for OAT sites (monetary and in-kind support equivalent to 0.23% of the total funding); Medtronic (Canada) donated stents for the Canadian sites (in-kind support equivalent to 0.29% of the total funding); Merck donated funding for the pilot phase and for training meetings (monetary support equivalent to 0.21% of the total funding); Millennium Pharmaceuticals and Schering-Plough donated replacement doses of eptifibatide (Integrilin) and funding for the pilot phase (in-kind and monetary support equivalent to 0.90% of the total funding); and Bristol-Myers Squibb Medical Imaging donated funding for the viability ancillary study, including supplemental funding and isotope donation (monetary and in-kind support equivalent to 1.49% of the total funding).
Dr. Hochman reports receiving consulting fees from Eli Lilly, Bristol-Myers Squibb, and Sanofi Aventis, speaking fees from the Network for Continuing Medical Education (supported by Bristol-Myers Squibb and Sanofi Aventis), and grant support to her institution for this study from Eli Lilly, Millennium Pharmaceuticals, Schering-Plough, Guidant, and Merck; Dr. Lamas, receiving speaking fees from Medtronic and Guidant and consulting fees from Medtronic; Dr. Buller, receiving consulting fees from Guidant; Dr. Dzavik, receiving consulting fees from Cordis (a Johnson & Johnson company) and Boston Scientific, speaking fees from Cordis, and grant support from Cordis and Medtronic; Dr. Ruzyllo, receiving consulting fees from Cordis and Procter & Gamble and speaking fees from Eli Lilly and Merck; Dr. Maggioni, receiving speaking fees from Guidant; Dr. White, receiving consulting fees and speaking fees from Sanofi Aventis and the Medicines Company and grant support from Fournier, Johnson & Johnson, Procter & Gamble, Schering-Plough, Alexion, Sanofi Aventis, Eli Lilly, Merck, the Medicines Company, Neuron, GlaxoSmithKline, Pfizer, and Roche; Dr. Rankin, receiving an unrestricted educational grant from Cordis; Dr. Renkin, receiving speaking fees from Guidant; Dr. Steg, receiving consulting fees and speaking fees from Merck and, as a national coordinator for a trial, honoraria from Schering-Plough; Dr. Leor, receiving consulting fees from BioLineRx; and Dr. Mark, receiving consulting fees and speaking fees from Medtronic and grant support from Eli Lilly. No other potential conflict of interest relevant to this article was reported.
This article was published at www.nejm.org on November 14, 2006.
We thank the patients who enrolled in the study, their physicians, and the staff at the study sites for their important contributions (the names of staff members at the study sites are listed in the Supplementary Appendix); the staff at the coordinating centers and core laboratories for their hard work; and R. Mansingh and E. Laurion for assistance in the preparation of the manuscript.
Source Information
From the Cardiovascular Clinical Research Center, New York University School of Medicine, New York (J.S.H., H.R.R., S.J.A.); Mount Sinai Medical Center, Miami Beach, FL (G.A.L.); Vancouver General Hospital, Vancouver, BC, Canada (C.E.B.); University Health Network, Toronto General Hospital, Toronto (V.D.); Maryland Medical Research Institute, Baltimore (S.F., G.L.K.); National Institute of Cardiology, Warsaw, Poland (W.R., Z.S.); Italian Association of Hospital Cardiologists Research Center, Florence (A.P.M.); Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand (H.W.); Hospital São Paulo, São Paulo (A.C.C.); Royal Perth Hospital, Perth, Australia (J.M.R.); Cliniques Universitaires St. Luc, Brussels (J.P.R.); Hôpital Bichat, Paris (P.G.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (A.M.M., G.S.); University Hospital, Basel, Switzerland (M.E.P.); Sheba Medical Center, Tel Hashomer, Israel (J.L.); Slovak Institute of Cardiovascular Disease, Bratislava (V.F.); and Duke Clinical Research Institute, Durham, NC (D.B.M.).
Address reprint requests to Dr. Hochman at the Cardiovascular Clinical Research Center, Leon Charney Division of Cardiology, New York University School of Medicine, 530 First Ave., HCC 1173, New York, NY 10016.
Investigators and committees of the Occluded Artery Trial (OAT) are listed in the Supplementary Appendix (available with the full text of this article at www.nejm.org).
- References
References
1
Eagle KA ,Goodman SG ,Avezum A ,Budaj A ,Sullivan CM ,Lopez-Sendon J . Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002;359:373-377
CrossRef | Web of Science | Medline2
Cohen M ,Gensini GF ,Maritz F , et al. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial. Circulation 2003;108:Suppl III:III-14
CrossRef3
Topol EJ ,Califf RM ,Vandormael M , et al. A randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation 1992;85:2090-2099
Web of Science | Medline4
Dzavik V ,Beanlands DS ,Davies RF , et al. Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (<6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS] -- a pilot study). Am J Cardiol 1994;73:856-861
CrossRef | Web of Science | Medline5
Horie H ,Takahashi M ,Minai K , et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation 1998;98:2377-2382
Web of Science | Medline6
Yousef ZR ,Redwood SR ,Bucknall CA ,Sulke AN ,Marber MS . Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study). J Am Coll Cardiol 2002;40:869-876
CrossRef | Web of Science | Medline7
Steg PG ,Thuaire C ,Himbert D , et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J 2004;25:2187-2194
CrossRef | Web of Science | Medline8
Cigarroa RG ,Lange RA ,Hillis LD . Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow. Am J Cardiol 1989;64:155-160
CrossRef | Web of Science | Medline9
Galvani M ,Ottani F ,Ferrini D ,Sorbello F ,Rusticali F . Patency of the infarct-related artery and left ventricular function as the major determinants of survival after Q-wave acute myocardial infarction. Am J Cardiol 1993;71:1-7
CrossRef | Web of Science | Medline10
Lamas GA ,Flaker GC ,Mitchell G , et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation 1995;92:1101-1109
Web of Science | Medline11
Puma JA ,Sketch MH Jr ,Thompson TD , et al. Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. Am J Cardiol 1999;83:482-487
CrossRef | Web of Science | Medline12
Berger AK ,Edris DW ,Breall JA ,Oetgen WJ ,Marciniak TA ,Molinari GF . Resource use and quality of care for Medicare patients with acute myocardial infarction in Maryland and the District of Columbia: analysis of data from the Cooperative Cardiovascular Project. Am Heart J 1998;135:349-356
CrossRef | Web of Science | Medline13
Guadagnoli E ,Hauptman PJ ,Ayanian JZ ,Pashos CL ,McNeil BJ ,Cleary PD . Variation in the use of cardiac procedures after acute myocardial infarction. N Engl J Med 1995;333:573-578
Full Text | Web of Science | Medline14
Pilote L ,Califf RM ,Sapp S , et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med 1995;333:565-572
Full Text | Web of Science | Medline15
Fox KA ,Goodman SG ,Anderson FA Jr , et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1414-1424
CrossRef | Web of Science | Medline16
Silva JC ,Rochitte CE ,Junior JS , et al. Late coronary artery recanalization effects on left ventricular remodelling and contractility by magnetic resonance imaging. Eur Heart J 2005;26:36-43
CrossRef | Web of Science | Medline17
White HD ,Braunwald E . Applying the open artery theory: use of predictive survival markers. Eur Heart J 1998;19:1132-1139
CrossRef | Web of Science | Medline18
Monteiro P ,Antunes A ,Goncalves LM ,Providencia LA . Long-term clinical impact of coronary-collateral vessels after acute myocardial infarction. Rev Port Cardiol 2003;22:1051-1061
Medline19
Porto I ,Selvanayagam JB ,Van Gaal WJ , et al. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, Thrombolysis in Myocardial Infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 2006;114:662-669
CrossRef | Web of Science | Medline20
Singh M ,Rihal CS ,Lennon RJ ,Garratt KN ,Mathew V ,Holmes DR Jr . Prediction of complications following nonemergency percutaneous coronary interventions. Am J Cardiol 2005;96:907-912
CrossRef | Web of Science | Medline21
Hochman JS ,Lamas GA ,Knatterud GL , et al. Design and methodology of the Occluded Artery Trial (OAT). Am Heart J 2005;150:627-642
CrossRef | Web of Science | Medline22
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Full Text | Web of Science | Medline23
Steinhubl SR ,Berger PB ,Mann JT III , et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420[Erratum, JAMA 2003;289:987.]
CrossRef | Web of Science | Medline24
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science25
Peto R ,Pike MC ,Armitage P , et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39
CrossRef | Web of Science | Medline26
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22027
Antman EM ,Anbe DT ,Armstrong PW , et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 2004;44:E1-E211
CrossRef | Medline28
Dzavik V, Buller CE, Lamas G, et al. Late revascularization of occluded infarct-related arteries to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 Trial. Circulation (in press).
29
Myocardial infarction redefined -- a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-1513
CrossRef | Web of Science | Medline30
Werner GS ,Emig U ,Mutschke O ,Schwarz G ,Bahrmann P ,Figulla HR . Regression of collateral function after recanalization of chronic total coronary occlusions: a serial assessment by intracoronary pressure and Doppler recordings. Circulation 2003;108:2877-2882
CrossRef | Web of Science | Medline31
Hochman JS ,Choo H . Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 1987;75:299-306
CrossRef | Web of Science | Medline32
Meijer A ,Verheugt FW ,van Eenige MJ ,Werter CJ . Left ventricular function at 3 months after successful thrombolysis: impact of reocclusion without reinfarction on ejection fraction, regional function, and remodeling. Circulation 1994;90:1706-1714
Web of Science | Medline33
Sabia PJ ,Powers ER ,Ragosta M ,Sarembock IJ ,Burwell LR ,Kaul S . An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992;327:1825-1831
Full Text | Web of Science | Medline34
Smith SC Jr ,Dove JT ,Jacobs AK , et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) -- executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001;103:3019-3041
Web of Science | Medline35
Pfisterer ME, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol (in press).
36
Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J (in press).
37
Kaltoft A ,Bottcher M ,Nielsen SS , et al. Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomized, controlled trial. Circulation 2006;114:40-47
CrossRef | Web of Science | Medline38
Stone GW ,Webb J ,Cox DA , et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 2005;293:1063-1072
CrossRef | Web of Science | Medline
- Citing Articles (171)
Citing Articles
1
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions 79:3, 453-495
CrossRef2
Ramon B van Loon, Gerrit Veen, Leo HB Baur, Otto Kamp, Jean GF Bronzwaer, Jos WR Twisk, Freek WA Verheugt, Albert C van Rossum. (2012) Improved clinical outcome after invasive management of patients with recent myocardial infarction and proven myocardial viability: primary results of a randomized controlled trial (VIAMI-trial). Trials 13:1, 1
CrossRef3
Leonarda Galiuto, Lazzaro Paraggio, Alberto R. Caterina, Elisa Fedele, Gabriella Locorotondo, Lucia Leccisotti, Alessandro Giordano, Antonio G. Rebuzzi, Filippo Crea. (2011) Positron Emission Tomography in Acute Coronary Syndromes. Journal of Cardiovascular Translational Research
CrossRef4
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 58:24, e44-e122
CrossRef5
Helene von Bibra, Martin St John Sutton. (2011) Impact of Diabetes on Postinfarction Heart Failure and Left Ventricular Remodeling. Current Heart Failure Reports 8:4, 242-251
CrossRef6
Adam H. Skolnick, Harmony R. Reynolds, Harvey D. White, Venu Menon, Antonio C. Carvalho, Aldo P. Maggioni, Camille A. Pearte, Luis Gruberg, Rudyney E.U. Azevedo, Erwin Schroeder, Sandra A. Forman, Gervasio A. Lamas, Judith S. Hochman, Vladimír Džavík. (2011) Comparison of Late Results of Percutaneous Coronary Intervention Among Stable Patients ≤65 Versus >65 Years of Age With an Occluded Infarct Related Artery (from the Occluded Artery Trial). The American Journal of Cardiology
CrossRef7
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology 58:24, 2550-2583
CrossRef8
Maame Yaa A.B. Yiadom. (2011) Emergency Department Treatment of Acute Coronary Syndromes. Emergency Medicine Clinics of North America 29:4, 699-710
CrossRef9
Roxana Mehran, Bimmer E. Claessen, Cosmo Godino, George D. Dangas, Kotaro Obunai, Sunil Kanwal, Mauro Carlino, José P.S. Henriques, Carlo Di Mario, Young-Hak Kim, Seung-Jung Park, Gregg W. Stone, Martin B. Leon, Jeffrey W. Moses, Antonio Colombo. (2011) Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions. JACC: Cardiovascular Interventions 4:9, 952-961
CrossRef10
Marcus Carlsson, Robert Jablonowski, Alastair J Martin, Philip C Ursell, Maythem Saeed. (2011) Coronary microembolization causes long-term detrimental effects on regional left ventricular function. Scandinavian Cardiovascular Journal 45:4, 205-214
CrossRef11
Esther S.H. Kim, Thomas P. Carrigan, Venu Menon. (2011) International Participation in Cardiovascular Randomized Controlled Trials Sponsored by the National Heart, Lung, and Blood Institute. Journal of the American College of Cardiology 58:7, 671-676
CrossRef12
Hisato Takagi, Takuya Umemoto. (2011) Percutaneous coronary intervention versus medical therapy for stable coronary artery disease: Meta-regression analysis of mortality and morbidity against stent use. International Journal of Cardiology 150:1, 90-92
CrossRef13
Francesco Borgia, Nicola Viceconte, Omar Ali, Claire Stuart-Buttle, Anjana Saraswathyamma, Rosario Parisi, Francesca Mirabella, Konstantinos Dimopoulos, Carlo Di Mario. (2011) Improved cardiac survival, freedom from mace and angina-related quality of life after successful percutaneous recanalization of coronary artery chronic total occlusions. International Journal of Cardiology
CrossRef14
Shigeo Horinaka. (2011) Use of Nicorandil in Cardiovascular Disease and Its Optimization. Drugs 71:9, 1105-1119
CrossRef15
Gerald S Werner. (2011) Outcomes following successful recanalization of chronic total coronary occlusions. Interventional Cardiology 3:3, 391-405
CrossRef16
G.S. Werner. (2011) Therapie des chronischen Koronararterienverschlusses. Herz 36:3, 222-231
CrossRef17
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef18
Gerald S. Werner. 2011. Chronic Total Coronary Occlusion. , 263-279.
CrossRef19
Neil Swanson, Anthony Gershlick. 2011. Primary and Rescue PCI in Acute Myocardial Infarction. , 242-261.
CrossRef20
James E. Udelson, Camille A. Pearte, Carey D. Kimmelstiel, Mariusz Kruk, Joseph A. Kufera, Sandra A. Forman, Anna Teresinska, Bartosz Bychowiec, Jose Antonio Marin-Neto, Thomas Höchtl, Eric A. Cohen, Paulo Caramori, Benita Busz-Papiez, Christopher Adlbrecht, Zygmunt P. Sadowski, Witold Ruzyllo, Debra J. Kinan, Gervasio A. Lamas, Judith S. Hochman. (2011) The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): Influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. American Heart Journal 161:3, 611-621
CrossRef21
Periklis Davlouros, Georgios Almpanis, Ioanna Xanthopoulou, Eleni Mavronasiou, George Hahalis, Dimitrios Alexopoulos. (2011) Long term outcome of routine early versus late transfer for coronary angiography following presumably successful thrombolysis for ST-segment elevation myocardial infarction. International Journal of Cardiology 147:2, 292-293
CrossRef22
Nihat Kalay, Ahmet Çelik, Tugrul Inanc, Ali Dogan, Ibrahim Ozdogru, Mehmet G. Kaya, Abdurrahman Oguzhan, Ramazan Topsakal, Ali Ergin. (2011) Left Ventricular Strain and Strain Rate Echocardiography Analysis in Patients with Total and Subtotal Occlusion in the Infarct-Related Left Anterior Descending Artery. Echocardiography 28:2, 203-209
CrossRef23
E. Marc Jolicœur, Micheal J Sketch, Daniel M Wojdyla, Sean P Javaheri, Shravan Nosib, Yuliya Lokhnygina, Manesh R. Patel, Linda K Shaw, James E Tcheng. (2011) Percutaneous coronary interventions and cardiovascular outcomes for patients with chronic total occlusions. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef24
Enrico Ammirati, Ornella E. Rimoldi, Paolo G. Camici. (2011) Is There Evidence Supporting Coronary Revascularization in Patients With Left Ventricular Systolic Dysfunction?. Circulation Journal 75:1, 3-10
CrossRef25
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef26
Yoko Irie, Kenya Sakamoto, Fumiyo Kubo, Takahiro Okusu, Takashi Katura, Yuichi Yamamoto, Yutaka Umayahara, Naoto Katakami, Hideaki Kaneto, Toshikazu Kashiyama, Yasunori Ueda, Keisuke Kosugi. (2011) Association of Coronary Artery Stenosis with Carotid Atherosclerosis in Asymptomatic Type 2 Diabetic Patients. Journal of Atherosclerosis and Thrombosis 18:4, 337-344
CrossRef27
M. Malach, W. J. Baumol. (2010) Further Opportunities for Cost Reduction of Medical Care. Journal of Community Health 35:6, 561-571
CrossRef28
Alessandro Fontanelli, Carlo Bonanno. (2010) Primary percutaneous coronary intervention in ‘early’ latecomers with ST-segment elevation acute myocardial infarction: the role of the infarct-related artery status. Journal of Cardiovascular Medicine1
CrossRef29
Stanley F. Fernandez, William E. Boden. (2010) Strategies in Stable Ischemic Heart Disease: Lessons from the COURAGE and BARI-2D Trials. Current Atherosclerosis Reports 12:6, 423-431
CrossRef30
, , W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, S. Garg, K. Huber, S. James, J. Knuuti, J. Lopez-Sendon, J. Marco, L. Menicanti, M. Ostojic, M. F. Piepoli, C. Pirlet, J. L. Pomar, N. Reifart, F. L. Ribichini, M. J. Schalij, P. Sergeant, P. W. Serruys, S. Silber, M. Sousa Uva, D. Taggart, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. Kolh, O. Alfieri, J. Dunning, S. Elia, P. Kappetein, U. Lockowandt, G. Sarris, P. Vouhe, , P. Kearney, L. von Segesser, S. Agewall, A. Aladashvili, D. Alexopoulos, M. J. Antunes, E. Atalar, A. Brutel de la Riviere, A. Doganov, J. Eha, J. Fajadet, R. Ferreira, J. Garot, J. Halcox, Y. Hasin, S. Janssens, K. Kervinen, G. Laufer, V. Legrand, S. A. M. Nashef, F.-J. Neumann, K. Niemela, P. Nihoyannopoulos, M. Noc, J. J. Piek, J. Pirk, Y. Rozenman, M. Sabate, R. Starc, M. Thielmann, D. J. Wheatley, S. Windecker, M. Zembala. (2010) Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 31:20, 2501-2555
CrossRef31
José T. Ortiz-Pérez, Amadeo Betriu, Daniel C. Lee, Teresa M. De Caralt, Sheridan N. Meyers, Charles J. Davidson, Rosario J. Perea, Marta Sitges, Xavier Bosch, Robert O. Bonow, Mónica Masotti, Josep Brugada, Edwin Wu. (2010) Angiographic and Magnetic Resonance Imaging Evaluation of In-Hospital Delay in Primary Percutaneous Intervention Delivery on Myocardial Salvage. The American Journal of Cardiology 106:7, 924-930
CrossRef32
Philippe Genereux, George Dangas. (2010) Antegrade, Retrograde, and Combination Strategies for Chronic Total Occlusions. Current Cardiology Reports 12:5, 429-439
CrossRef33
Usman Baber, Annapoorna S. Kini, Samin K. Sharma. (2010) Stenting of complex lesions: an overview. Nature Reviews Cardiology 7:9, 485-496
CrossRef34
Michael S. Lauer. (2010) The historical and moral imperatives of comparative effectiveness research. Statistics in Medicine 29:19, 1982-1984
CrossRef35
Gerald Werner, Matthias Hochadel, Uwe Zeymer, Sebastian Kerber, Burghard Schumacher, Eberhard Grube, Karl Hauptmann, Martin Brueck, Ralf Zahn, Jochen Senges. (2010) Contemporary success and complication rates of percutaneous coronary intervention for chronic total coronary occlusions: results from the ALKK quality control registry of 2006. EuroIntervention 6:3, 361-366
CrossRef36
Alex Hobson, Nick Curzen. 2010. Acute Coronary Syndromes and Myocardial Infarction. , 234-255.
CrossRef37
Kazuo Kimura, Masami Kosuge, Jyun Okuda. (2010) Percutaneous coronary intervention in ST-segment elevation myocardial infarction. Cardiovascular Intervention and Therapeutics 25:2, 53-59
CrossRef38
Dominique Joyal, Jonathan Afilalo, Stéphane Rinfret. (2010) Effectiveness of recanalization of chronic total occlusions: A systematic review and meta-analysis. American Heart Journal 160:1, 179-187
CrossRef39
Freek WA Verheugt. (2010) Timing of angiography after fibrinolysis for ST-elevation acute myocardial infarction. Current Opinion in Cardiology 25:4, 302-304
CrossRef40
Heart Failure Society of America. (2010) Section 5: Management of Asymptomatic Patients with Reduced Left Ventricular Ejection Fraction. Journal of Cardiac Failure 16:6, e57-e60
CrossRef41
Robert O. Bonow. (2010) 2009 ASNC keynote lecture: Measuring cost, cost-effectiveness, and quality in cardiovascular imaging. Journal of Nuclear Cardiology 17:3, 362-369
CrossRef42
Marc Cohen, Catalin Boiangiu, Mateen Abidi. (2010) Therapy for ST-Segment Elevation Myocardial Infarction Patients Who Present Late or Are Ineligible for Reperfusion Therapy. Journal of the American College of Cardiology 55:18, 1895-1906
CrossRef43
David M. Holzhey, Stephan Jacobs, Thomas Walther, Friedrich W. Mohr, Volkmar Falk. (2010) Is Chronic Total Coronary Occlusion a Risk Factor for Long-Term Outcome After Minimally Invasive Bypass Grafting of the Left Anterior Descending Artery?. The Annals of Thoracic Surgery 89:5, 1496-1501
CrossRef44
Marek Prech, Andrzej Marszałek, Josef Schröder, Violetta Filas, Maciej Lesiak, Marek Jemielity, Aleksander Araszkiewicz, Stefan Grajek. (2010) Apoptosis as a Mechanism for the Elimination of Cardiomyocytes After Acute Myocardial Infarction. The American Journal of Cardiology 105:9, 1240-1245
CrossRef45
BENJAMIN G. ROMICK, VANKEEPURAM S. SRINIVAS. (2010) Functionally Unrevascularized Chronic Total Occlusions: A Step Closer to Indentifying the CTO Patient Who Benefits from PCI. Journal of Interventional Cardiology 23:2, 149-151
CrossRef46
Günter Pilz, Tobias Heer, Elisabeth Harrer, Markus Klos, Berthold Höfling. (2010) Beneficial effect of delayed reperfusion in ST elevation myocardial infarction despite transmural necrosis documented in cardiac magnetic resonance imaging. Clinical Research in Cardiology 99:4, 251-255
CrossRef47
Patrick T. O'Gara. (2010) The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial. Journal of the American College of Cardiology 55:13, 1359-1361
CrossRef48
Matthias G. Friedrich. (2010) Current status of cardiovascular magnetic resonance imaging in the assessment of coronary vasculature. Canadian Journal of Cardiology 26, 51A-55A
CrossRef49
M. L. Simoons, S. Windecker. (2010) Chronic stable coronary artery disease: drugs vs. revascularization. European Heart Journal 31:5, 530-541
CrossRef50
Giora Weisz, Jeffrey W. Moses. (2010) Contemporary principles of coronary chronic total occlusion recanalization. Catheterization and Cardiovascular Interventions 75:S1, S21-S27
CrossRef51
Austin Leach, Michael Chester. 2010. Chest Pain Syndromes. , 292-307.
CrossRef52
Matthias E Pfisterer, Michael J Zellweger, Bernard J Gersh. (2010) Management of stable coronary artery disease. The Lancet 375:9716, 763-772
CrossRef53
Darryn L Appleton, Giuseppe GL Biondi-Zoccai, Antonio Abbate. (2010) Benefits of coronary revascularization in stable patients in the short and long term after acute myocardial infarction. Interventional Cardiology 2:1, 67-76
CrossRef54
Craig A. Thompson. (2010) Percutaneous Revascularization of Coronary Chronic Total Occlusions. JACC: Cardiovascular Interventions 3:2, 152-154
CrossRef55
David Rosenmann, David Meerkin, Yaron Almagor. 2010. Chronic Total Occlusion. , 40-52.
CrossRef56
Pierre-Frédéric Keller, Marco Roffi. 2010. Acute Coronary Syndromes. , 1-22.
CrossRef57
Young-Jo Kim. (2010) Reperfusion Strategies in Acute ST-segment Elevation Myocardial Infarction. Journal of the Korean Medical Association 53:3, 196
CrossRef58
Mariusz Kruk, Christopher E. Buller, James Enlou Tcheng, Vladimir Dzavík, Venugopal Menon, G.B. John Mancini, Sandra A. Forman, Peter Kurray, Benita Busz-Papiez, Gervasio A. Lamas, Judith S. Hochman. (2010) Impact of Left Ventricular Ejection Fraction on Clinical Outcomes Over Five Years After Infarct-Related Coronary Artery Recanalization (from the Occluded Artery Trial [OAT]). The American Journal of Cardiology 105:1, 10-16
CrossRef59
Farouk Mookadam, Sherif E. Moustafa. (2009) Prevention of late postmyocardial infarction left ventricular remodeling: An update. Current Heart Failure Reports 6:4, 245-253
CrossRef60
O. Gaemperli, L. Husmann, T. Schepis, P. Koepfli, I. Valenta, W. Jenni, H. Alkadhi, T. F. Luscher, P. A. Kaufmann. (2009) Coronary CT angiography and myocardial perfusion imaging to detect flow-limiting stenoses: a potential gatekeeper for coronary revascularization?. European Heart Journal 30:23, 2921-2929
CrossRef61
Jorge A. Belardi. (2009) An IVUS look for impossible chronic total occlusions. Catheterization and Cardiovascular Interventions 74:6, 879-880
CrossRef62
Amit Kumar, Christopher P. Cannon. (2009) Acute Coronary Syndromes: Diagnosis and Management, Part II. Mayo Clinic Proceedings 84:11, 1021-1036
CrossRef63
Amar Krishnaswamy, A. Michael Lincoff, Venu Menon. (2009) Magnitude and consequences of missing the acute infarct-related circumflex artery. American Heart Journal 158:5, 706-712
CrossRef64
Deepak Thomas, Robert P. Giugliano. (2009) Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. American Heart Journal 158:5, 695-705
CrossRef65
Irene Lang, Sandra Forman, Aldo Maggioni, Witold Ruzyllo, Jean Renkin, Carlos Vozzi, P. Gabriel Steg, Jose-Maria Hernandez-Garcia, Krzysztof Zmudka, Manuel Jimenez-Navarro, George Sopko, Gervasio Lamas, Judith Hochman. (2009) Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT). EuroIntervention 5:5, 610-618
CrossRef66
Marco Tubaro, Anna Sonia Petronio. (2009) ST-segment elevation myocardial infarction management in Europe. Journal of Cardiovascular Medicine 10:Suppl 1, S3-S6
CrossRef67
Jeffrey W Moses. (2009) On the misinterpretation of clinical trials. Interventional Cardiology 1:1, 3-5
CrossRef68
S. Michael Gharacholou, Karen P. Alexander. (2009) Evolving role of revascularization in older adults with acute coronary syndrome. Current Cardiovascular Risk Reports 3:5, 355-365
CrossRef69
Carlo Di Mario. (2009) Informed consent in interventional cardiology. EuroIntervention 5:4, 415-416
CrossRef70
David E. Kandzari. (2009) Import and Export of Interventional Technique. JACC: Cardiovascular Interventions 2:9, 843-845
CrossRef71
Grace A Lin, Rita F Redberg. (2009) Use of stress testing prior to percutaneous coronary intervention in patients with stable coronary artery disease. Expert Review of Cardiovascular Therapy 7:9, 1061-1066
CrossRef72
Rohit Seth Loomba, Rohit Arora. (2009) ST Elevation Myocardial Infarction Guidelines Today: A Systematic Review Exploring Updated ACC/AHA STEMI Guidelines and Their Applications. American Journal of Therapeutics 16:5, e7-e13
CrossRef73
Monte Malach, W. J. Baumol. (2009) Opportunities for the Cost Reduction of Medical Care. Journal of Community Health 34:4, 255-261
CrossRef74
Matthew A. Cavender, Sarah Milford-Beland, Matthew T. Roe, Eric D. Peterson, William S. Weintraub, Sunil V. Rao. (2009) Prevalence, Predictors, and In-Hospital Outcomes of Non-Infarct Artery Intervention During Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (from the National Cardiovascular Data Registry). The American Journal of Cardiology 104:4, 507-513
CrossRef75
G. Takemura, M. Nakagawa, H. Kanamori, S. Minatoguchi, H. Fujiwara. (2009) Benefits of reperfusion beyond infarct size limitation. Cardiovascular Research 83:2, 269-276
CrossRef76
Andreas Wolfgang Schoenenberger, Richard Kobza, Peiman Jamshidi, Michel Zuber, Antonio Abbate, Andreas Ernst Stuck, Matthias Pfisterer, Paul Erne. (2009) Sudden Cardiac Death in Patients With Silent Myocardial Ischemia After Myocardial Infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). The American Journal of Cardiology 104:2, 158-163
CrossRef77
Gerald S. Werner, Anselm K. Gitt, Uwe Zeymer, Claus Juenger, Frank Towae, Harm Wienbergen, Jochen Senges. (2009) Chronic total coronary occlusions in patients with stable angina pectoris: impact on therapy and outcome in present day clinical practice. Clinical Research in Cardiology 98:7, 435-441
CrossRef78
C. Richard Conti. (2009) Some Clinical Trials Get No Respect. Clinical Cardiology 32:7, 356-357
CrossRef79
Verheugt, Freek W.A., . (2009) Routine Angioplasty after Fibrinolysis — How Early Should “Early” Be?. New England Journal of Medicine 360:26, 2779-2781
Full Text80
F. Van de Werf. (2009) Year 2008 ESC ST-segment elevation myocardial infarction guidelines: implications for the interventional cardiologist--from evidence to recommendations and practice. European Heart Journal Supplements 11:Suppl C, C31-C37
CrossRef81
M. Busk, A. Kaltoft, S. S. Nielsen, M. Bottcher, M. Rehling, L. Thuesen, H. E. Botker, J. F. Lassen, E. H. Christiansen, L. R. Krusell, H. R. Andersen, T. T. Nielsen, S. D. Kristensen. (2009) Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs. 12-72 h. European Heart Journal 30:11, 1322-1330
CrossRef82
Vladimír Dz̆avík, Christopher E. Buller, Gerard Devlin, Ronald G. Carere, G.B. John Mancini, Warren J. Cantor, Pawel E. Buszman, James M. Rankin, Carlos Vozzi, John R. Ross, Sandra Forman, Bruce A. Barton, A. Gervasio A. Lamas, Judith S. Hochman. (2009) Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. Catheterization and Cardiovascular Interventions 73:6, 771-779
CrossRef83
Lukasz A. Malek, Harmony R. Reynolds, Sandra A. Forman, Carlos Vozzi, G.B. John Mancini, John K. French, Mieczyslaw Dziarmaga, Jean P. Renkin, Janusz Kochman, Gervasio A. Lamas, Judith S. Hochman. (2009) Late coronary intervention for totally occluded left anterior descending coronary arteries in stable patients after myocardial infarction: Results from the Occluded Artery Trial (OAT). American Heart Journal 157:4, 724-732
CrossRef84
Christoph Klein, Eike Nagel, Rolf Gebker, Sebastian Kelle, Bernhard Schnackenburg, Kristof Graf, Stefan Dreysse, Eckart Fleck. (2009) Magnetic Resonance Adenosine Perfusion Imaging in Patients After Coronary Artery Bypass Graft Surgery. JACC: Cardiovascular Imaging 2:4, 437-445
CrossRef85
Tracy Y. Wang, Min Zhang, Yuling Fu, Paul W. Armstrong, L. Kristin Newby, C. Michael Gibson, David J. Moliterno, Frans Van de Werf, Harvey D. White, Robert A. Harrington, Matthew T. Roe. (2009) Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non–ST-elevation acute coronary syndromes undergoing diagnostic angiography. American Heart Journal 157:4, 716-723
CrossRef86
John K. French, Jennifer A. Shearer. (2009) Are we letting good stories obscure the truth—Can qualitative techniques provide clarification?. American Heart Journal 157:4, 597-598
CrossRef87
Warren J. Cantor, Sergio B. Baptista, Vankeepuram S. Srinivas, Camille A. Pearte, Venu Menon, Zygmunt Sadowski, John R. Ross, Peter Meciar, Eugenia Nikolsky, Sandra A. Forman, Gervasio A. Lamas, Judith S. Hochman. (2009) Impact of stress testing before percutaneous coronary intervention or medical management on outcomes of patients with persistent total occlusion after myocardial infarction: Analysis from the occluded artery trial. American Heart Journal 157:4, 666-672
CrossRef88
George C.M. Siontis, Athina Tatsioni, Demosthenes G. Katritsis, John P.A. Ioannidis. (2009) Persistent reservations against contradicted percutaneous coronary intervention indications: Citation content analysis. American Heart Journal 157:4, 695-701
CrossRef89
(2009) Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST. Revista Española de Cardiología 62:3, 293.e1-293.e47
CrossRef90
Michael S. Lauer. (2009) Comparative Effectiveness Research: The View From the NHLBI. Journal of the American College of Cardiology 53:12, 1084-1086
CrossRef91
Mark, Daniel B., Pan, Wenqin, Clapp-Channing, Nancy E., Anstrom, Kevin J., Ross, John R., Fox, Rebecca S., Devlin, Gerard P., Martin, C. Edwin, Adlbrecht, Christopher, Cowper, Patricia A., Ray, Linda Davidson, Cohen, Eric A., Lamas, Gervasio A., Hochman, Judith S., . (2009) Quality of Life after Late Invasive Therapy for Occluded Arteries. New England Journal of Medicine 360:8, 774-783
Full Text92
Glickman, Seth W., McHutchison, John G., Peterson, Eric D., Cairns, Charles B., Harrington, Robert A., Califf, Robert M., Schulman, Kevin A., . (2009) Ethical and Scientific Implications of the Globalization of Clinical Research. New England Journal of Medicine 360:8, 816-823
Full Text93
Allen Jeremias, Sanjay Kaul, Todd K. Rosengart, Luis Gruberg, David L. Brown. (2009) The Impact of Revascularization on Mortality in Patients with Nonacute Coronary Artery Disease. The American Journal of Medicine 122:2, 152-161
CrossRef94
A. A. Boshchenko, A. V. Vrublevsky, R. S. Karpov. (2009) Transthoracic echocardiography in the detection of chronic total coronary artery occlusion. European Journal of Echocardiography 10:1, 62-68
CrossRef95
Leonard Schwartz. (2009) Therapeutic options in coronary artery disease: Focusing on the guidelines. Canadian Journal of Cardiology 25:1, 19-24
CrossRef96
Smiljana V. Pavlovic, Dragana P. Sobic-Saranovic, Branko D. Beleslin, Miodrag C. Ostojic, Milan A. Nedeljkovic, Vojislav L. Giga, Zorica R. Petrasinovic, Vera M. Artiko, Mila V. Todorovic-Tirnanic, Vladimir B. Obradovic. (2009) One-year follow-up of myocardial perfusion and function evaluated by gated SPECT MIBI in patients with earlier myocardial infarction and chronic total occlusion. Nuclear Medicine Communications 30:1, 68-75
CrossRef97
Li-Tang Kuo, Shih-Jen Chen, Wen-Jin Cherng, Ning-I Yang, Chen-Chin Lee, Chi-Wen Cheng, Subodh Verma, Chao-Hung Wang. (2009) Late Reperfusion of A Totally Occluded Infarct-Related Artery Increases Granulocyte-Colony Stimulation Factor and Reduces Stroma-Derived Factor-1α Blood Levels in Patients With Ongoing Ischemia After Acute Myocardial Infarction. International Heart Journal 50:4, 433-444
CrossRef98
Dorinna D. Mendoza, Wm. Guy Weigold. (2009) Evaluation of myocardial viability by multidetector CT. Journal of Cardiovascular Computed Tomography 3:1, S2-S12
CrossRef99
Y. Louvard, T. Lefèvre. (2008) Pourquoi faire des angioplasties d’occlusions coronaires chroniques et comment ?. Annales de Cardiologie et d'Angéiologie 57:6, 341-351
CrossRef100
Florian Schwarz, Balazs Ruzsics, U. Joseph Schoepf, Gorka Bastarrika, Salvatore A. Chiaramida, Joseph A. Abro, Robin L. Brothers, Sebastian Vogt, Bernhard Schmidt, Philip Costello, Peter L. Zwerner. (2008) Dual-energy CT of the heart—Principles and protocols. European Journal of Radiology 68:3, 423-433
CrossRef101
Vinod Jorapur, Terje K. Steigen, Christopher E. Buller, Vladimír Dẑavík, John G. Webb, Bradley H. Strauss, Eunice E.S. Yeoh, Peter Kurray, Leszek Sokalski, Mauricio C. Machado, Shari S. Kronsberg, Gervasio A. Lamas, Judith S. Hochman, G.B. John Mancini. (2008) Distribution and determinants of myocardial perfusion grade following late mechanical recanalization of occluded infarct-related arteries postmyocardial infarction: A report from the occluded artery trial. Catheterization and Cardiovascular Interventions 72:6, 783-789
CrossRef102
Axel de Labriolle, Laurent Bonello, Probal Roy, Gilles Lemesle, Daniel H. Steinberg, Zhenyi Xue, Kimberly Kaneshige, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Joseph Lindsay, Ron Waksman. (2008) Comparison of Safety, Efficacy, and Outcome of Successful Versus Unsuccessful Percutaneous Coronary Intervention in “True” Chronic Total Occlusions. The American Journal of Cardiology 102:9, 1175-1181
CrossRef103
Claudio Moretti, Giuseppe GL Biondi-zoccai, Filippo Sciuto, Pierluigi Omedè, Maria Teresa Lucciola, Luisa Morena, Walter Grosso Marra, Gian Paolo Trevi, Imad Sheiban. (2008) Appraising the pathophysiologic impact of coronary collaterals as measured by fractional flow reserve on symptoms and signs of myocardial ischemia. Journal of Cardiovascular Medicine 9:11, 1120-1126
CrossRef104
William E Boden, Vipul Gupta. (2008) Reperfusion strategies in acute ST-segment elevation myocardial infarction. Current Opinion in Cardiology 23:6, 613-619
CrossRef105
, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, A. Kastrati, A. Rosengren, P. G. Steg, M. Tubaro, F. Verheugt, F. Weidinger, M. Weis, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , S. Silber, F. V. Aguirre, N. Al-Attar, E. Alegria, F. Andreotti, W. Benzer, O. Breithardt, N. Danchin, C. D. Mario, D. Dudek, D. Gulba, S. Halvorsen, P. Kaufmann, R. Kornowski, G. Y. H. Lip, F. Rutten. (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:. European Heart Journal 29:23, 2909-2945
CrossRef106
R. Valenti, A. Migliorini, U. Signorini, R. Vergara, G. Parodi, N. Carrabba, G. Cerisano, D. Antoniucci. (2008) Impact of complete revascularization with percutaneous coronary intervention on survival in patients with at least one chronic total occlusion. European Heart Journal 29:19, 2336-2342
CrossRef107
J.R. González-Juanatey, E. González Babarro. (2008) ¿Qué ha cambiado en Cardiología en el último año? Implicaciones para la práctica clínica. Revista Clínica Española 208, 3-8
CrossRef108
Demosthenes G. Katritsis, Bernhard Meier. (2008) Percutaneous Coronary Intervention for Stable Coronary Artery Disease. Journal of the American College of Cardiology 52:11, 889-893
CrossRef109
Albert Schömig, Julinda Mehilli, Antoinette de Waha, Melchior Seyfarth, Jürgen Pache, Adnan Kastrati. (2008) A Meta-Analysis of 17 Randomized Trials of a Percutaneous Coronary Intervention-Based Strategy in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology 52:11, 894-904
CrossRef110
Kamal Sharma, Mark J. Eisenberg. (2008) Putting the benefits of percutaneous coronary revascularization into perspective: From trials to guidelines. Current Cardiology Reports 10:5, 393-401
CrossRef111
Antonio Abbate, Giuseppe G.L. Biondi-Zoccai, Darryn L. Appleton, Paul Erne, Andreas W. Schoenenberger, Michael J. Lipinski, Piefrancesco Agostoni, Imad Sheiban, George W. Vetrovec. (2008) Reply. Journal of the American College of Cardiology 52:7, 580-582
CrossRef112
Harvey D White, Derek P Chew. (2008) Acute myocardial infarction. The Lancet 372:9638, 570-584
CrossRef113
William Keeble, Isabelle VonderMuhll, Ian Paterson. (2008) Biventricular apical thrombi demonstrated by contrast-enhanced cardiac MRI following anteroapical STEMI and unsuccessful reperfusion therapy. Canadian Journal of Cardiology 24:8, S51-S53
CrossRef114
G. S. Werner. (2008) Chronischer Koronarverschluss: Neue Techniken und Strategien. Clinical Research in Cardiology Supplements 3:1, 78-84
CrossRef115
Vladimír Džavík, P. Gabriel Steg, Bruce Barton, Gervasio Lamas, Judith S. Hochman. (2008) A Meta-Analysis That Misses the Mark. Journal of the American College of Cardiology 52:7, 578-580
CrossRef116
Megan Coylewright, Roger S. Blumenthal, Wendy Post. (2008) Placing COURAGE in Context: Review of the Recent Literature on Managing Stable Coronary Artery Disease. Mayo Clinic Proceedings 83:7, 799-805
CrossRef117
David P. Faxon. (2008) New data on early management of patients with ST-elevation myocardial infarction. Current Cardiology Reports 10:4, 291-298
CrossRef118
Anthony A Bavry, Deepak L Bhatt. (2008) Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. The Lancet 371:9630, 2134-2143
CrossRef119
Marc A. Brouwer, Peter C. Kievit, Hendrik-Jan Dieker, Gerrit Veen, Aart J. Karreman, Freek W.A. Verheugt. (2008) Sustained coronary patency after fibrinolytic therapy as independent predictor of 10-year cardiac survival. American Heart Journal 155:6, 1039-1046
CrossRef120
H.-R. Arntz. (2008) Reperfusion strategies in ST-elevation myocardial infarction—Current status and perspectives for early and pre-hospital treatment. Resuscitation 77:3, 296-305
CrossRef121
David M. Safley, John A. House, Steven P. Marso, J. Aaron Grantham, Barry D. Rutherford. (2008) Improvement in Survival Following Successful Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions: Variability by Target Vessel. JACC: Cardiovascular Interventions 1:3, 295-302
CrossRef122
V. Menon, C. A. Pearte, C. E. Buller, Ph.G. Steg, S. A. Forman, H. D. White, P. N. Marino, D. G. Katritsis, P. Caramori, R. Lasevitch, K. Loboz-Grudzien, A. Zurakowski, G. A. Lamas, J. S. Hochman. (2008) Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. European Heart Journal 30:2, 183-191
CrossRef123
H.C. Lowe, S.B. Freedman. (2008) The late open artery hypothesis: the case and the artery remain closed. European Heart Journal 30:2, 129-130
CrossRef124
Darryn L. Appleton, Antonio Abbate, Giuseppe G.L. Biondi-Zoccai. (2008) Late percutaneous coronary intervention for the totally occluded infarct-related artery: A meta-analysis of the effects on cardiac function and remodeling. Catheterization and Cardiovascular Interventions 71:6, 772-781
CrossRef125
Gerald Werner, Carlo Di Mario, Alfredo Galassi, Anthony Gershlick, Bernhard Reimers, George Sianos, Horst Sievert, Thierry Lefevre, Nicolaus Reifart. (2008) Chronic total coronary occlusions and the Occluded Artery Trial. A critical appraisal.. EuroIntervention 4:1, 23-27
CrossRef126
Nishith K. Singh. (2008) Some Patients with Persistent Coronary Artery Occlusion After Acute Myocardial Infarction May Require Revascularization. Clinical Cardiology 31:5, 232-232
CrossRef127
David J. Moliterno. (2008) Late percutaneous recanalization of totally occluded infarct-related arteries—More than about time. Catheterization and Cardiovascular Interventions 71:6, 782-783
CrossRef128
Pedro A. Lemos. (2008) Recanalization of chronically occluded coronaries: A step forward in understanding its impact. Catheterization and Cardiovascular Interventions 71:6, E5-E6
CrossRef129
William Wijns. (2008) Percutaneous Cardiovascular Intervention. The time has come for a big change.... EuroIntervention 4:1, 17-21
CrossRef130
Darryn Appleton, Antonio Abbate, Giuseppe G.L. Biondi-Zoccai, Sara Delcré, Mario Bollati, Imad Sheiban, Pierfrancesco Agostoni. (2008) Revisiting the role of percutaneous revascularization versus medical therapy for later infarct-related artery occlusion (letter of comment on Ioannidis and Katritsis. Am Heart J. 2007;154:1065-71). American Heart Journal 155:4, e41
CrossRef131
William E. Boden, David J. Maron. (2008) Reducing Post-Myocardial Infarction Mortality in the Elderly. Journal of the American College of Cardiology 51:13, 1255-1257
CrossRef132
Antonio Abbate, Giuseppe G.L. Biondi-Zoccai, Darryn L. Appleton, Paul Erne, Andreas W. Schoenenberger, Michael J. Lipinski, Pierfrancesco Agostoni, Imad Sheiban, George W. Vetrovec. (2008) Survival and Cardiac Remodeling Benefits in Patients Undergoing Late Percutaneous Coronary Intervention of the Infarct-Related Artery. Journal of the American College of Cardiology 51:9, 956-964
CrossRef133
E. Marc Jolicoeur, Christopher B. Granger, Timothy D. Henry, David J. Holmes, Carl J. Pepine, Daniel Mark, Bernard R. Chaitman, Bernard J. Gersh, E. Magnus Ohman. (2008) Clinical and research issues regarding chronic advanced coronary artery disease. American Heart Journal 155:3, 418-434
CrossRef134
Javier Bermejo, Javier Segovia, Fernando Alfonso. (2008) Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association 2007 (Orlando, EE.UU., 4-7 de noviembre de 2007). Revista Española de Cardiología 61:2, 185-193
CrossRef135
Carlo Di Mario, Dariusz Dudek, Federico Piscione, Waldemar Mielecki, Stefano Savonitto, Ernesto Murena, Konstantinos Dimopoulos, Antonio Manari, Achille Gaspardone, Andrzej Ochala, Krzysztof Zmudka, Leonardo Bolognese, Philippe Gabriel Steg, Marcus Flather. (2008) Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. The Lancet 371:9612, 559-568
CrossRef136
Ganesan Karthikeyan, Balram Bhargava. (2008) Taking interventional cardiology forward: hindsight, foresight and insight. EuroIntervention 3:4, 424-425
CrossRef137
Sammy Elmariah, Sidney C Smith, Valentin Fuster. (2008) Late medical versus interventional therapy for stable ST-segment elevation myocardial infarction. Nature Clinical Practice Cardiovascular Medicine 5:1, 42-52
CrossRef138
(2008) 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 71:1, E1-E40
CrossRef139
Elliott M. Antman, Mary Hand, Paul W. Armstrong, Eric R. Bates, Lee A. Green, Lakshmi K. Halasyamani, Judith S. Hochman, Harlan M. Krumholz, Gervasio A. Lamas, Charles J. Mullany, David L. Pearle, Michael A. Sloan, Sidney C. Smith. (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 51:2, 210-247
CrossRef140
Spencer B. King, Sidney C. Smith, John W. Hirshfeld, Alice K. Jacobs, Douglass A. Morrison, David O. Williams. (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 51:2, 172-209
CrossRef141
Ulrich Laufs, Holger Nef, Helge Möllmann, Florian Custodis, Michael Böhm. (2008) Clinical Trial Updates and Hotline Sessions presented at the Scientific Session 2007 of the American heart association. Clinical Research in Cardiology 97:1, 1-11
CrossRef142
D CUTLER. (2007) The lifetime costs and benefits of medical technology
. Journal of Health Economics 26:6, 1081-1100
CrossRef143
Theodore D. Fraker, Stephan D. Fihn. (2007) 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina. Journal of the American College of Cardiology 50:23, 2264-2274
CrossRef144
IMAD SHEIBAN, CLAUDIO MORETTI, PIERLUIGI OMEDÉ, FILIPPO SCIUTO, MARIO BOLLATI, ANTONIO LAUDITO, GIAN PAOLO TREVI, GIUSEPPE G.L. BIONDI-ZOCCAI. (2007) The Retrograde Coronary Approach for Chronic Total Occlusions: Mid-Term Results and Technical Tips & Tricks. Journal of Interventional Cardiology 20:6, 466-473
CrossRef145
James M. Brophy. (2007) Risk stratification following non-ST segment elevation myocardial infarction: Is the glass half-full or half-empty?. Canadian Journal of Cardiology 23:13, 1080-1081
CrossRef146
John J. Mahmarian. (2007) Computed Tomography Coronary Angiography as an Anatomic Basis for Risk Stratification. Journal of the American College of Cardiology 50:12, 1171-1173
CrossRef147
William E. Boden, Kim Eagle, Christopher B. Granger. (2007) Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:10, 917-929
CrossRef148
Gary E Rosenthal, Peter Cram. (2007) Is weekend hospital admission associated with increased mortality in patients with acute myocardial infarction?. Nature Clinical Practice Cardiovascular Medicine 4:8, 412-413
CrossRef149
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef150
Masahiko Ochiai. (2007) Retrograde approach for chronic total occlusion: present status and prospects. EuroIntervention 3:2, 169-173
CrossRef151
C. Richard Conti. (2007) Some Patients with Persistent Coronary Artery Occlusion after Acute Myocardial Infarction may Require Revascularization. Clinical Cardiology 30:8, 371-372
CrossRef152
Simon R. Dixon, Cindy L. Grines, William W. O’Neill. (2007) The Year in Interventional Cardiology. Journal of the American College of Cardiology 50:3, 270-285
CrossRef153
E. V. Gelfand, C. P. Cannon. (2007) Myocardial infarction: contemporary management strategies. Journal of Internal Medicine 262:1, 59-77
CrossRef154
John J. Mahmarian, Craig M. Pratt. (2007) Reply. Journal of the American College of Cardiology 49:22, 2227-2228
CrossRef155
Barry A. Franklin. (2007) Lessons Learned From the COURAGE Trial: Generalizability, Limitations, and Implications. Preventive Cardiology 10:3, 117-120
CrossRef156
Mark J. Eisenberg. (2007) Substitution of Fractionated for Unfractionated Heparin During High-Risk Percutaneous Coronary Intervention. Journal of the American College of Cardiology 49:23, 2247-2248
CrossRef157
David J Maron. (2007) Does late PCI improve clinical outcome and survival in patients with arterial occlusion after MI?. Nature Clinical Practice Cardiovascular Medicine 4:5, 250-251
CrossRef158
(2007) Persistent Coronary Occlusion after Myocardial Infarction. New England Journal of Medicine 356:16, 1681-1684
Full Text159
Hochman, Judith S., Steg, P. Gabriel, . (2007) Does Preventive PCI Work?. New England Journal of Medicine 356:15, 1572-1574
Full Text160
Boden, William E., O'Rourke, Robert A., Teo, Koon K., Hartigan, Pamela M., Maron, David J., Kostuk, William J., Knudtson, Merril, Dada, Marcin, Casperson, Paul, Harris, Crystal L., Chaitman, Bernard R., Shaw, Leslee, Gosselin, Gilbert, Nawaz, Shah, Title, Lawrence M., Gau, Gerald, Blaustein, Alvin S., Booth, David C., Bates, Eric R., Spertus, John A., Berman, Daniel S., Mancini, G.B. John, Weintraub, William S., . (2007) Optimal Medical Therapy with or without PCI for Stable Coronary Disease. New England Journal of Medicine 356:15, 1503-1516
Full Text161
K. Graf, E. Fleck. (2007) Akuter Myokardinfarkt und „Open-Artery-Hypothese“. Clinical Research in Cardiology Supplements 2:2, 120-122
CrossRef162
Giora Weisz, Jeffrey W Moses. (2007) New percutaneous approaches for chronic total occlusion of coronary arteries. Expert Review of Cardiovascular Therapy 5:2, 231-241
CrossRef163
(2007) Late reperfusion does not provide benefit after myocardial infarction. Nature Clinical Practice Cardiovascular Medicine 4:3, 120-121
CrossRef164
Javier Bermejo, Javier Segovia, Magda Heras, Fernando Alfonso. (2007) Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Chicago, Estados Unidos, 12-15 de noviembre de 2006). Revista Española de Cardiología 60:2, 157-167
CrossRef165
Chul-Min Kim. (2007) The Open Artery Hypothesis. Korean Circulation Journal 37:6, 235
CrossRef166
Javier Bermejo, Javier Segovia, Magda Heras, Fernando Alfonso. (2007) Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Chicago, USA, November 12-15, 2006). Revista Española de Cardiología (English Edition) 60:2, 157-167
CrossRef167
Jun Shiraishi, Yoshio Kohno, Takahisa Sawada, Shinya Nishizawa, Masayasu Arihara, Mitsuyoshi Hadase, Masayuki Hyogo, Takakazu Yagi, Takatomo Shima, Takashi Okada, Satoaki Matoba, Hiroyuki Yamada, Tetsuya Tatsumi, Makoto Kitamura, Keizo Furukawa, Hiroaki Matsubara, The AMI-Kyoto Multi-Center Risk Stu. (2007) In-Hospital Outcomes of Primary Percutaneous Coronary Interventions Performed at Hospitals With and Without On-Site Coronary Artery Bypass Graft Surgery. Circulation Journal 71:8, 1208-1212
CrossRef168
Markus Haass. (2007) Highlights of the late-breaking clinical trials from the 2006 Scientific Sessions of the American Heart Association. Future Cardiology 3:1, 31-34
CrossRef169
W.H. Frishman. (2007) Coronary Intervention for Persistent Occlusion after Myocardial Infarction. Yearbook of Medicine 2007, 347-350
CrossRef170
B.J. Gersh. (2007) Coronary Intervention for Persistent Occlusion after Myocardial Infarction. Yearbook of Cardiology 2007, 207-209
CrossRef171
Hillis, L. David, Lange, Richard A., . (2006) Myocardial Infarction and the Open-Artery Hypothesis. New England Journal of Medicine 355:23, 2475-2477
Full Text
- Letters
